AR080388A1 - Derivados de imidazol aza-biciclicos sustituidos que resultan utiles como moduladores del receptor trpm8 - Google Patents
Derivados de imidazol aza-biciclicos sustituidos que resultan utiles como moduladores del receptor trpm8Info
- Publication number
- AR080388A1 AR080388A1 ARP110100720A ARP110100720A AR080388A1 AR 080388 A1 AR080388 A1 AR 080388A1 AR P110100720 A ARP110100720 A AR P110100720A AR P110100720 A ARP110100720 A AR P110100720A AR 080388 A1 AR080388 A1 AR 080388A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- hydrogen
- fluorinated
- chlorine
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 102000003610 TRPM8 Human genes 0.000 title 1
- 101150111302 Trpm8 gene Proteins 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 17
- 239000001257 hydrogen Substances 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 5
- 239000000460 chlorine Chemical group 0.000 abstract 5
- 229910052801 chlorine Inorganic materials 0.000 abstract 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 208000004454 Hyperalgesia Diseases 0.000 abstract 4
- 230000002757 inflammatory effect Effects 0.000 abstract 4
- 208000035154 Hyperesthesia Diseases 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Chemical group 0.000 abstract 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- -1 4-methyl- piperidin-1-yl Chemical group 0.000 abstract 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 206010053552 allodynia Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000000392 somatic effect Effects 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a derivados sustituidos de imidazol aza-bicilicos, a las composiciones farmacéuticas que los contienen y a su uso en el tratamiento de los trastornos y afecciones moduladas por PRT M8 (Receptor de potencial transitorio, subfamilia de la melastina, tipo 8) incluso, por ejemplo, el dolor inflamatorio, hiperalgesia inflamatoria, hipersensibilidad inflamatoria, dolor neuropático, alodinia al frío neuropática, hiperalgesia somática inflamatoria, hiperalgesia visceral inflamatoria, enfermedades cardiovasculares agravadas por el frío y enfermedad pulmonar agravada por el frío. Reivindicacion 1: Un compuesto de Formula (1) en donde R1 se selecciona del grupo que consiste de hidrogeno, fluor, cloro, alquilo C1-4 fluorado y alcoxi C1-4 fluorado; R2 se selecciona del grupo que consiste de hidrogeno, cloro, bromo, alquilo C1-4, alquilo C1-4 fluorado y alcoxi C1-4 fluorado; siempre y cuando R2 no es hidrogeno, entonces el resto de formula (2) es el compuesto de formula (3); el resto de formula (2) se selecciona del grupo que consiste de (4) en donde R3 se selecciona del grupo que consiste de hidrogeno, cloro, ciano, alquilo C1-4, alquilo C1-4 fluorado, alcoxi C1-4, alcoxi C1-4 fluorado, -O-(CH2)2-OH, -O-CH2-CO2H, -O-(CH2)2-O-(alquilo C1-4), -O-CH2-(alquilo C1-2 fluorado), -O-(CH2)2-NRARB y -NRARB; en donde RA y RB se seleccionan, independientemente, del grupo que consiste de hidrogeno y alquilo C1-4; alternativamente RA y RB se toman en forma conjunta con el átomo de nitrogeno al cual están unidos para formar una estructura anular seleccionada del grupo compuesto por pirrolidin-1-ilo, piperidin-1-ilo, piperazin-1-ilo, 4-metil-piperidin-1-ilo, 4-metil-piperazin-1-ilo y morfolin-4-ilo; Q es una estructura anular sustituida opcionalmente seleccionada del grupo que consiste de formulas (5) hasta (12); (5);(6); en donde R5 es alquilo C1-4; R6 se selecciona del grupo que consiste de alquilo C1-4 y alquilo C1-4 fluorado; y se R7 selecciona del grupo que consiste de hidrogeno, cloro, fluor, ciano, alquilo C1-4 y alcoxi C1-4; (7) en donde R8 y R9 se seleccionan independientemente del grupo que consiste de alquilo C1-4; (8); en donde R10 es alquilo C1-4; y R11 se selecciona del grupo que consiste de hidrogeno y ciano; (9); en donde R12 y R13 se seleccionan independientemente del grupo que consiste de hidrogeno y alquilo C1-4; (10); en donde R14 es alquilo C1-4; (11); en donde R15 es alquilo C1-4; y R16 se selecciona del grupo que consiste de hidrogeno, cloro y bromo; y (12); en donde R17 es alquilo C1-4; o un solvato, hidrato, tautomero o sal aceptada farmacéuticamente de éstos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31087010P | 2010-03-05 | 2010-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080388A1 true AR080388A1 (es) | 2012-04-04 |
Family
ID=43875233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100720A AR080388A1 (es) | 2010-03-05 | 2011-03-09 | Derivados de imidazol aza-biciclicos sustituidos que resultan utiles como moduladores del receptor trpm8 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8680098B2 (es) |
| EP (1) | EP2542552B1 (es) |
| JP (1) | JP5782054B2 (es) |
| KR (1) | KR101667277B1 (es) |
| CN (1) | CN102884063B (es) |
| AR (1) | AR080388A1 (es) |
| AU (1) | AU2011223566B2 (es) |
| BR (1) | BR112012022369A2 (es) |
| CA (1) | CA2791715C (es) |
| DK (1) | DK2542552T3 (es) |
| ES (1) | ES2654399T3 (es) |
| MX (3) | MX348957B (es) |
| NZ (1) | NZ601998A (es) |
| TW (1) | TWI567071B (es) |
| UY (1) | UY33264A (es) |
| WO (1) | WO2011109587A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8680098B2 (en) * | 2010-03-05 | 2014-03-25 | Janssen Pharmaceutica, Nv | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators |
| GB2573597B8 (en) | 2015-06-22 | 2025-08-06 | Time Machine Capital Ltd | Auditory augmentation system |
| JP6454418B2 (ja) * | 2015-06-23 | 2019-01-16 | キッセイ薬品工業株式会社 | ピラゾール誘導体、またはその薬理学的に許容される塩 |
| CN117088871A (zh) * | 2018-11-30 | 2023-11-21 | 四川科伦博泰生物医药股份有限公司 | 并环化合物、其制备方法及用途 |
| CN110638807A (zh) * | 2019-08-23 | 2020-01-03 | 陈明英 | 局部镇痛用药物组合物、其制备方法及其应用 |
| US12455295B2 (en) | 2023-08-17 | 2025-10-28 | Rosemount Aerospace Inc. | Conformal multi-function air-data probes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
| US6566367B2 (en) * | 2000-12-12 | 2003-05-20 | Pfizer Inc. | Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines |
| EP1460067A4 (en) * | 2001-11-26 | 2005-12-07 | Takeda Pharmaceutical | BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| US7582761B2 (en) | 2002-10-17 | 2009-09-01 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP2007513105A (ja) | 2003-12-02 | 2007-05-24 | ユ セ ベ ソシエテ アノニム | イミダゾール誘導体、その製法及び使用 |
| AR050630A1 (es) * | 2004-09-09 | 2006-11-08 | Solvay Pharm Bv | DERIVADOS DE 6- TRIFLUOROMETIL PURINA 2- SUSTITUIDA CON ACTIVIDAD ANTAGONISTA DE ADENOSINA-A3. PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS. |
| GB0508472D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| EP1891048A1 (en) | 2005-06-11 | 2008-02-27 | Vernalis (R&D) Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| HRP20151078T1 (hr) | 2006-03-22 | 2015-11-20 | F. Hoffmann - La Roche Ag | Pirazoli kao 11-beta-hsd-1 |
| US20080139608A1 (en) | 2006-12-06 | 2008-06-12 | Universiteit Leiden | 2,6,8, Trisubstituted 1-deazapurines and their different uses |
| AU2008253311A1 (en) | 2007-05-18 | 2008-11-27 | Bayer Schering Pharma Aktiengesellshaft | Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| PT2242759E (pt) | 2008-02-06 | 2012-12-17 | Astrazeneca Ab | Compostos |
| PL2294066T3 (pl) | 2008-04-28 | 2015-02-27 | Janssen Pharmaceutica Nv | Benzimidazole jako inhibitory hydroksylazy prolilowej |
| US8680098B2 (en) * | 2010-03-05 | 2014-03-25 | Janssen Pharmaceutica, Nv | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators |
-
2011
- 2011-02-25 US US13/034,922 patent/US8680098B2/en active Active
- 2011-03-03 CA CA2791715A patent/CA2791715C/en active Active
- 2011-03-03 DK DK11709244.5T patent/DK2542552T3/en active
- 2011-03-03 WO PCT/US2011/026974 patent/WO2011109587A1/en not_active Ceased
- 2011-03-03 ES ES11709244.5T patent/ES2654399T3/es active Active
- 2011-03-03 MX MX2016000495A patent/MX348957B/es unknown
- 2011-03-03 NZ NZ601998A patent/NZ601998A/en not_active IP Right Cessation
- 2011-03-03 KR KR1020127025999A patent/KR101667277B1/ko not_active Expired - Fee Related
- 2011-03-03 EP EP11709244.5A patent/EP2542552B1/en active Active
- 2011-03-03 BR BR112012022369A patent/BR112012022369A2/pt not_active Application Discontinuation
- 2011-03-03 MX MX2015000028A patent/MX336354B/es unknown
- 2011-03-03 MX MX2012010270A patent/MX2012010270A/es active IP Right Grant
- 2011-03-03 JP JP2012556235A patent/JP5782054B2/ja not_active Expired - Fee Related
- 2011-03-03 CN CN201180022551.2A patent/CN102884063B/zh not_active Expired - Fee Related
- 2011-03-03 AU AU2011223566A patent/AU2011223566B2/en not_active Ceased
- 2011-03-04 TW TW100107247A patent/TWI567071B/zh not_active IP Right Cessation
- 2011-03-09 UY UY0001033264A patent/UY33264A/es unknown
- 2011-03-09 AR ARP110100720A patent/AR080388A1/es unknown
-
2014
- 2014-02-04 US US14/172,395 patent/US9023846B2/en active Active
-
2015
- 2015-02-17 US US14/623,671 patent/US9409915B2/en not_active Expired - Fee Related
-
2016
- 2016-06-29 US US15/196,262 patent/US9718820B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012010270A (es) | 2013-04-24 |
| US20110218197A1 (en) | 2011-09-08 |
| MX336354B (es) | 2016-01-14 |
| ES2654399T3 (es) | 2018-02-13 |
| UY33264A (es) | 2011-09-30 |
| CA2791715C (en) | 2018-05-15 |
| WO2011109587A1 (en) | 2011-09-09 |
| MX348957B (es) | 2017-07-04 |
| KR20130018750A (ko) | 2013-02-25 |
| US9023846B2 (en) | 2015-05-05 |
| US20150158875A1 (en) | 2015-06-11 |
| CN102884063B (zh) | 2015-11-25 |
| AU2011223566A1 (en) | 2012-09-20 |
| TWI567071B (zh) | 2017-01-21 |
| AU2011223566B2 (en) | 2015-05-21 |
| EP2542552A1 (en) | 2013-01-09 |
| DK2542552T3 (en) | 2017-12-11 |
| US8680098B2 (en) | 2014-03-25 |
| NZ601998A (en) | 2014-03-28 |
| CA2791715A1 (en) | 2011-09-09 |
| CN102884063A (zh) | 2013-01-16 |
| BR112012022369A2 (pt) | 2017-08-29 |
| EP2542552B1 (en) | 2017-11-15 |
| JP5782054B2 (ja) | 2015-09-24 |
| US9409915B2 (en) | 2016-08-09 |
| KR101667277B1 (ko) | 2016-10-18 |
| TW201144309A (en) | 2011-12-16 |
| JP2013521306A (ja) | 2013-06-10 |
| US20160304518A1 (en) | 2016-10-20 |
| US20140155395A1 (en) | 2014-06-05 |
| US9718820B2 (en) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080388A1 (es) | Derivados de imidazol aza-biciclicos sustituidos que resultan utiles como moduladores del receptor trpm8 | |
| ES2695182T3 (es) | Derivados de sulfamoil tiofenamida y su uso como medicamentos para tratar la hepatitis B | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| CL2009000127A1 (es) | Compuestos derivados de [indol, azaindol]-2-carboxamida sustituidos con un grupo silanilo; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento del dolor, inflamacion, trastornos metabolicos, entre otras enfermedades mediadas por la modulacion del receptor trpv1. | |
| JP2012522847A5 (es) | ||
| AR044005A1 (es) | Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden | |
| AR109931A1 (es) | Compuesto inhibidor de la prostaglandina d sintasa hematopoyética (h-pgds), composición farmacéutica que lo comprende y uso del compuesto para fabricar un medicamento | |
| HRP20110498T1 (hr) | Azetidini kao inhibitori mek za liječenje proliferativnih bolesti | |
| IL264541A (en) | History of sulfamolepyrolamide and their use as drugs for the treatment of jaundice b | |
| ES2885474T3 (es) | Derivados de sibirilina para la utilización en la prevención y/o tratamiento de trastornos asociados a la necroptosis celular | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR068054A1 (es) | Compuestos de pirrolopirimidina | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR064452A1 (es) | Derivados de 1,2,4 oxadiazol-indol,composiciones farmaceuticas que los comprenden y usos en trastornos asociados a receptores s1p1. | |
| MX383885B (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirosina cinasa (trk). | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR008162A1 (es) | Compuestos activos derivados de indazol sustituido, composiciones farmaceuticas que los contienen y compuesto util para su preparacion | |
| EA201100698A1 (ru) | Производные тиенотриазолодиазепина, активные в отношении апо а1 | |
| MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| EA201170374A1 (ru) | Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний | |
| SV2010003779A (es) | Inhibidores de ciclopropil-polimerasa ref. tipo193 pct/slv/fd/1vh | |
| AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
| EA201690515A1 (ru) | Производные диазокарбазола в качестве пэт-лигандов белка tau | |
| AR114420A1 (es) | Derivados de 2,4-diaminoquinazolina y usos médicos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |